Navigation Links
Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
Date:6/12/2008

f May 21, 2008, 235 patients remained on belimumab treatment in the continuation study.

In June 2006, HGS reported the 52-week results of the Phase 2 trial, which demonstrated that belimumab significantly reduced disease activity versus placebo in patients with serologically active SLE across multiple clinical measures, exhibited clinically relevant biological activity, and appeared generally safe and well tolerated. Frequency and severity of adverse events were similar to placebo. Among the findings at Week 52 was a significantly improved response rate among serologically active patients, as defined by an improvement in SELENA SLEDAI score of 4 points or greater, no new BILAG A flare and no more than one new BILAG B flare, and no worsening in Physician's Global Assessment. This combination of measures is the primary efficacy endpoint in the ongoing pivotal Phase 3 clinical trials.

About LymphoStat-B (belimumab)

LymphoStat-B (belimumab) is a human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator, or BLyS(R). BLyS is a naturally occurring protein discovered by HGS that is required for the development of B-lymphocyte cells into mature plasma B cells. Plasma B cells produce antibodies, the body's first line of defense against infection.

In lupus and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies - antibodies that attack and destroy the body's own healthy tissues. The presence of autoantibodies appears to correlate with disease severity. Pre-clinical and clinical studies demonstrate that B-cell antagonists can reduce autoantibody levels and help control autoimmune disease activity.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes nove
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
3. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
4. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
5. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
6. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. First Human Implant of New Archus Orthopedics Facet Replacement System
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013   Upsher-Smith Laboratories, Inc. ... its global Phase III clinical trial for ... for the management of epilepsy in adults, ... is specifically engineered to provide convenient once-daily ... levels observed with currently available treatment options.  ...
(Date:5/22/2013)... 22, 2013 MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) ... about some recent company developments. As Medifirst continues to ... communication with shareholders. Integrating social media into its investor ... and will post updates on Twitter.  The Facebook homepage ... Says CEO Bruce J. ...
(Date:5/22/2013)... TORONTO , May 22, 2013  Generex ... three presentations demonstrating the superiority of the AE37 breast ... Express, Inc. ( www.antigenexpress.com ). The presentations will be ... of Clinical Oncology (ASCO) to be held in ... 4, 2013. The presentation entitled " Booster ...
Breaking Medicine Technology:Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Medifirst Solutions, Inc. Announces Update To Shareholders 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4
... N. J. ,Oct. 14, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical ... developer, manufacturer and marketer of medical devices worldwide, today ... hand-held M series ultrasound platforms at the American Society ... October 14-18, 2011. The M7 ...
... MAHWAH, N.J., Oct. 14, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray ... a leading developer, manufacturer and marketer of medical ... A3 anesthesia system, an expansion of its A ... that complements Mindray,s broad range of ultrasound and ...
Cached Medicine Technology:Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA 2Mindray Announces Expansion of its A Series Anesthesia Portfolio 2
(Date:5/22/2013)... Over the next two decades, the cost of treating ... than double, topping more than $180 billion a year, ... the increase: an aging population. The report, from the ... was published May 22 in the journal Stroke ... system," Dr. Bruce Ovbiagele, chairman of the department of ...
(Date:5/22/2013)... Award Presented at the 2013 Annual ... here: http://bit.ly/13DkFfk , Merrill Corporation is pleased ... Product/Service of the Year” at the 7th M&A Advisor ... Hotel in Palm Beach, Florida. , Merrill DataSite ... solution that optimizes the due diligence process and ...
(Date:5/22/2013)... 22, 2013 Hurricane preparation isn’t just ... That’s why Amica Insurance is reminding everyone ... upcoming hurricane season. , “An important part of hurricane ... a senior assistant vice president at Amica Insurance. “The ... the threat of a storm.” , Flood damage is ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Finding trustworthy, loving ... parents can do for their children. To help parents in ... chock-full of information about their nurturing programs, staff and ... captures the warm spirit of Paty’s Daycare,” said Patricia “Auntie ... feel welcome when you visit the new website, from the ...
(Date:5/22/2013)... May 22, 2013 Unknown to the citizens ... at 30 mph. Minutes before it struck, the city’s ... nearing threat. This gave them time to reach safety and ... is proud to provide a product that will increase ... Wheelock SAFEPATH® SP40S Emergency Evacuation System provides employees ...
Breaking Medicine News(10 mins):Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3Health News:Reviewing Insurance Policies: a Key Part of Hurricane Preparations 2Health News:Paty’s Daycare Launches New Website to Connect with Parents in Need of Nurturing Child Care 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2
... Hospira, Inc. (NYSE: HSP ), a leading global ... host a conference call to discuss its second-quarter 2009 results on ... , , The company will release its second-quarter 2009 results ... conference call. , , A live webcast of the ...
... military readiness, harms the health of soldiers and veterans, ... of Defense and Veterans Affairs, these agencies should implement ... goal of a tobacco-free military, says a new report ... phase in a ban on tobacco use in the ...
... Ormco Corporation, a subsidiary of Danaher Corporation (NYSE: ... jury verdict in its patent infringement case against Align Technology, ... to straighten teeth. The jury unanimously found that Align,s ... a patent held by Ormco. The claims at issue ...
... 26 Warner Chilcott Limited announced today that it will ... Meeting") and a Special Court-Ordered Meeting of Shareholders (the "Special ... the Company,s shareholders will be asked to vote in favor ... Company from Bermuda to Ireland. Subject to shareholder approval ...
... Calif., June 26 Align Technology, Inc. (Nasdaq: ... against Align in a lawsuit brought by Ormco Corporation (Ormco) ... for the Central District of California (District Court). Ormco alleged ... non-infringement, invalidity, as well as unenforceability of the patent. ...
... R.I., June 26 CVS Caremark (NYSE: ... been named as one of the nation,s leading corporations for innovative ... their families to make better choices about their own health and ... ) , , CVS Caremark received the ...
Cached Medicine News:Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 2Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 3Health News:Jury Renders Verdict for Ormco - Align's Invisalign(R) Product Infringes Ormco Patent 2Health News:Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders 2Health News:Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 3
... for laboratories looking for time and cost ... operation in terms of easy reagent cassette ... on-board stability., ,URISYS 2400 is a ... capability for medium to high volume laboratories ...
... The Small Joint Ball Electrode ... in small joint applications. With its ... tip, controlled capsuloligamentous or tendinous tissue ... When used in conjunction with the ...
Acufex arthroscopic electrodes are insulated for use in all fluids and come in boxes of 10....
... The Assistant Free ... retractors utilizing Velcro® straps. ... of the surgeon's operative ... personnel. Three retractor styles ...
Medicine Products: